Companies DiaMedica Therapeutics
DiaMedica Therapeutics (DMAC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me DiaMedica Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,215,161FY2023
- $1,550,985FY2024
- $2,727,350FY2025
CEO total pay was $2,727,350 in fiscal 2025, up from $1,550,985 in fiscal 2024.
FY2025: salary $645,000 · bonus $0 · stock awards $0 · option awards $1,652,400
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Rick Pauls | $645,000 | $0 | $0 | $1,652,400 | $412,500 | $0 | $17,450 | $2,727,350 |
| President and Chief Executive Officer | ||||||||
| Julie Krop | 198,980 | 0 | 0 | 1,421,100 | 79,592 | 0 | 7,891 | 1,707,563 |
| Chief Medical Officer | ||||||||
| Scott Kellen | 408,500 | 0 | 0 | 619,650 | 183,920 | 0 | 17,450 | 1,229,520 |
| Chief Financial Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Rick Pauls | $2,727,350 | $1,550,985 | $1,215,161 | ↑ +1,176,365 |
| Julie Krop | 1,707,563 | — | — | — |
| Scott Kellen | 1,229,520 | 813,955 | 632,215 | ↑ +415,565 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
DiaMedica's executive compensation policies, plans and programs seek to enhance financial performance and shareholder value by aligning the financial interests of executives with those of shareholders and emphasizing pay-for-performance. The company emphasizes that a significant portion of executive compensation is at risk and paid in equity, while avoiding guaranteed salary increases, bonuses, or perquisites.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Scott Kellen | Option | 7,500 | 2.45 | — |
| Rick Pauls | Option | 22,124 | 2.45 | — |
| Scott Kellen | Option | 25,125 | 2.73 | — |
| Rick Pauls | Option | 67,875 | 2.73 | — |
| Scott Kellen | Option | 81,250 | 2.9 | — |
| Rick Pauls | Option | 187,500 | 2.9 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel O’ConnorIndependent · Nominating and Corporate Governance · Audit · Compensation (Chair) | $56,104 | $0 | $302,169 | — | $0 | $358,273 |
| James ParsonsIndependent · Board Chair · Audit Committee (Chair) | 85,000 | 2,703 | 112,195 | — | 0 | 199,898 |
| Michael Giuffre, M.DIndependent · Nominating and Corporate Governance (Chair) · Scientific & Clinical Research | 58,000 | 1,844 | 88,574 | — | 0 | 148,418 |
| Charles Semba, M.DIndependent · Audit · Compensation · Scientific and Clinical Research | 56,500 | 898 | 88,574 | — | 0 | 145,972 |
| Richard Kuntz, M.DIndependent · Compensation · Scientific and Clinical Research (Chair) | 53,000 | 1,687 | 88,574 | — | 0 | 143,261 |
| Tanya LewisIndependent · Compensation Committee · Nominating and Corporate Governance Committee · Scientific and Clinical Research Committee | 53,000 | 0 | 88,574 | — | 0 | 141,574 |
| Rick PaulsEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $361,604 |
| Equity awards (grant-date value) | $7,132 |
| All other compensation | $0 |
| Total cost of the board | $368,736 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names DiaMedica Therapeutics as a peer
Companies that benchmark against DMAC
No companies currently name DMAC as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Mineralys Therapeutics, Inc. | 2025 | Jon Congleton | $636,500 | $0 | $4,435,626 | $472,601 | $5,544,727 |
| 2 | Anavex Life Sciences Corp. | 2025 | Christopher Missling | 723,485 | 0 | 3,083,000 | 0 | 3,959,085 |
| 3 | PepGen Inc. | 2025 | James McArthur | 619,000 | 170,620 | 2,088,547 | 0 | 3,316,783 |
| 4 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 5 | DiaMedica Therapeutics | 2025 | Rick Pauls | 645,000 | 0 | 1,652,400 | 412,500 | 2,727,350 |
| 6 | Vigil Neuroscience, Inc. | 2024 | Ivana Magovčević-Liebisch | 620,000 | 0 | 1,692,871 | 306,900 | 2,633,571 |
| 7 | Inozyme Pharma, Inc. | 2024 | Douglas Treco | 541,667 | 0 | 1,933,375 | 0 | 2,485,392 |
| 8 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 9 | Alto Neuroscience, Inc. | 2025 | Amit Etkin | 650,671 | 0 | 934,186 | 358,072 | 2,188,487 |
| 10 | Lineage Cell Therapeutics, Inc. | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 11 | Acumen Pharmaceuticals, Inc. | 2025 | Daniel O'Connell | 646,354 | 412,482 | 478,338 | 305,725 | 1,863,567 |
| 12 | Galectin Therapeutics Inc. | 2025 | Joel Lewis | 624,000 | 182,763 | — | — | 1,174,782 |
| 13 | Applied Therapeutics, Inc. | 2024 | Les Funtleyder | 530,625 | 153,000 | 132,000 | 0 | 1,053,846 |
| 14 | Ovid Therapeutics Inc | 2025 | Margaret Alexander | 515,000 | 24,806 | 118,466 | 350,000 | 1,022,272 |
| — | Tourmaline Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Immunic, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Annovis Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | MediciNova, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| DiaMedica Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Acumen Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Alto Neuroscience, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Anavex Life Sciences Corp. | not disclosed | Option 100 | not disclosed | not disclosed |
| Annovis Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Applied Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | AON Radford Global Compensation Consulting |
| Fulcrum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Galectin Therapeutics Inc. | 100% | not disclosed | not disclosed | Barney & Barney LLC |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Immunic, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Inozyme Pharma, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Lineage Cell Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Anderson |
| MediciNova, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Mineralys Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Ovid Therapeutics Inc | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLP |
| PepGen Inc. | not disclosed | not disclosed | not disclosed | Pay Governance, LLC |
| Tourmaline Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Vigil Neuroscience, Inc. | not disclosed | Option 100 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | 9,928,381 | 271,093 | 149,163 | 97.34% | Passed |
| 2025 | 2025-05-15 | 6,536,608 | 398,959 | 11,788 | 94.25% | Passed |
| 2024 | 2024-05-22 | 13,178,728 | 564,691 | 254,912 | 95.89% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-20 | 97.34%a |
| 2025 | 2025-05-15 | 94.25%b |
| 2024 | 2024-05-22 | 95.89%c |
a. Approved under the standard stated in the filing — “Proposal Three : Advisory Vote to Approve Executive Compensation -- Affirmative vote of a majority of votes cast on the proposal | Abstentions: Abstentions will have no effect.”.
b. Approved under the standard stated in the filing — “Voting Proposal Votes Required Effect of Votes Withheld/Against Effect of Abstentions Effect of Broker Non- Votes Voting Proposal One : Election of Directors Affirmative vote of a majority of votes cast on the voting proposal. || Abstentions: Abstentions will have no effect.”.
c. Approved under the standard stated in the filing — “Voting Proposal Five : Approval, on an Advisory Basis, of the Frequency of Future Advisory Votes on Executive Compensation -- Affirmative vote of a majority of votes cast on the choice of frequency. | Abstentions: Abstentions will have no effect.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (29 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Rick Pauls. DEF 14A, filed 2026-04-01. Section “Summary Compensation Table” · page 46. As printed: 2,727,350. View filing ↗
- Section 01, Julie Krop. DEF 14A, filed 2026-04-01. Section “Summary Compensation Table” · page 46. As printed: 1,707,563. View filing ↗
- Section 01, Scott Kellen. DEF 14A, filed 2026-04-01. Section “Summary Compensation Table” · page 46. As printed: 1,229,520. View filing ↗
- Section 08, Daniel O’Connor. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 358,273. View filing ↗
- Section 08, James Parsons. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 199,898. View filing ↗
- Section 08, Michael Giuffre, M.D. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 148,418. View filing ↗
- Section 08, Charles Semba, M.D. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 145,972. View filing ↗
- Section 08, Richard Kuntz, M.D. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 143,261. View filing ↗
- Section 08, Tanya Lewis. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 141,574. View filing ↗
- Section 08, Rick Pauls. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-21. Item 5.07 · say-on-pay result. As reported: 97.34% (votes for as printed: 9,928,381). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-15. Item 5.07 · say-on-pay result. As reported: 94.25% (votes for as printed: 6,536,608). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-23. Item 5.07 · say-on-pay result. As reported: 95.89% (votes for as printed: 13,178,728). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 361,604 + equity 7,132 + all other 0 = 368,736, summed across the director compensation table rows.
- Mineralys Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Mineralys Therapeutics, Inc.'s own proxy. As printed: 5,544,727. View filing ↗
- Anavex Life Sciences Corp., Section 10b CEO total. DEF 14A, filed 2026-08-11. CEO total compensation as printed in Anavex Life Sciences Corp.'s own proxy. As printed: 3,959,085. View filing ↗
- PepGen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in PepGen Inc.'s own proxy. As printed: 3,316,783. View filing ↗
- Fulcrum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗
- DiaMedica Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in DiaMedica Therapeutics's own proxy. As printed: 2,727,350. View filing ↗
- Vigil Neuroscience, Inc., Section 10b CEO total. DEF 14A, filed 2025-03-31. CEO total compensation as printed in Vigil Neuroscience, Inc.'s own proxy. As printed: 2,633,571. View filing ↗
- Inozyme Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Alto Neuroscience, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in Alto Neuroscience, Inc.'s own proxy. As printed: 2,188,487. View filing ↗
- Lineage Cell Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Lineage Cell Therapeutics, Inc.'s own proxy. As printed: 2,111,170. View filing ↗
- Acumen Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Acumen Pharmaceuticals, Inc.'s own proxy. As printed: 1,863,567. View filing ↗
- Galectin Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-10-13. CEO total compensation as printed in Galectin Therapeutics Inc.'s own proxy. As printed: 1,174,782. View filing ↗
- Applied Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Applied Therapeutics, Inc.'s own proxy. As printed: 1,053,846. View filing ↗
- Ovid Therapeutics Inc, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Ovid Therapeutics Inc's own proxy. As printed: 1,022,272. View filing ↗